medigraphic.com
ISSN 1527-3172 (Digital)

2016, Número 3

<< Anterior Siguiente >>

MEDICC Review 2016; 18 (3)


The ABCs of clinical trials in Cuba

Gorry C

Idioma: Ingles.
Referencias bibliográficas: 16
Paginas: 9-14
Archivo PDF: 199.51 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. For a detailed explanation of this strategy, see “Connecting Science to Population Health: The ‘Closed Loop’ Approach,” by Augustín Lage, MEDICC Rev. 2007 Fall;9(1):48.

  2. For complete list of Cuban biotech WIPO Gold Medal Award winners, see http://www.ocpi.cu./sites/default/fi les/archivos_a_vincular/medallasoro.pdf

  3. Pascual MA, Jimenez G, Torres A, Fors MM, López I. Cuba’s National Clinical Trials Coordinating Center: Emergence, Evolution and Main Results. MEDICC Rev [Internet]. 2010 Apr-Jun [cited 2016 Jun 21];13(1):46–51. Available from: http://www.medicc.org/mediccreview/index.php?issue=15&id=184&a=va

  4. Ministry of Public Health (CU). Anuario Estadístico de Salud, 2015. Havana: Ministry of Public Health (CU). 2016. Spanish.

  5. Pascual MA. Los ensayos clínicos en Cuba: Impacto en la biotecnología y en la salud pública [unpublished Master’s thesis]. [Havana]: [place unknown]; 2013. Spanish.

  6. 6.World Health Organization. Cuban experience with local production of medicines, technology transfer and improving access to health. Geneva: World Health Organization; 2015.

  7. Suarez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B et al. Clinical Experience with Nimotuzumab in Cuban Pediatric Patients with Brain Tumors, 2005 to 2007. MEDICC Rev [Internet]. 2009 Summer [cited 2016 17 Jul]; 11(3):27–33. Available from: http://www.medicc.org/mediccreview/index .php?issue=9&id=102&a=va

  8. Granma Internacional. Clinical trials of promising Cuban monoclonal antibody expanded. Granma [Internet]. 2016 Apr 7 [cited 2016 Jun 21]. Available from: http://en.granma.cu/cuba/2016-04-07/clinical-trials-of-promising-cuban-mono clonal-antibody-expanded

  9. EFE. Cuba begins 3rd phase of clinical trials of treatment for prostate cancer. EFE [Internet] 2015 Aug 19 [cited 2016 Jul 4]. Available from: http://www.efe.com/efe/english/life/cuba-begins-3rd-phase-of-clinical-trials-treatment-for -prostate-cancer/50000263-2691573

  10. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical Development and Perspectives of CIMAvax-EGF, Cuban Vaccine for Non-small-cell Lung Cancer Therapy. MEDICC Rev [Internet]. 2010 Winter [cited 2016 Jun 4]; 12(1):17–23. Available from: http://www.medicc.org/mediccreview/index .php?issue=11&id=128&a=va

  11. Gorry C. Cuba’s Complex Respiratory Picture. Lancet Resp Med. 2015 Sept; 3.

  12. Lee K. A small boat in a large ocean: One US cancer center’s ongoing journey to bring Cuban cancer vaccines to American patients [PowerPoint presented at the 14th Edition of the Series of Conversations: Cuba in US Foreign Policy]; Havana: 2015 Dec 16.

  13. Raices Pérez-Castañeda M. Papel de la organización superior de desarrollo empresarial BioCubaFarma en la concreción dentro de la sociedad cubana de proyectos biotecnológicos orientados al benefi cio social [PowerPoint]; 2015. Spanish.

  14. Berlanga J. Fernández JI, López E, López PA, del Río A, et al. Heberprot- P: A Novel Product for Treating Advanced Diabetic Foot Ulcer. MEDICC Rev [Internet]. 2013 Jan [cited 2016 Jul 3]; 15(1):11–5. Available from: http://www .medicc.org/mediccreview/index.php?issue=23&id=287&a=va

  15. Reed GA. Let’s open the door to Cuba and its promising diabetes treatments. SF Chronicle [Internet]. 2016 Mar 17 [cited 2016 Jul 16]. Available from: http:// www.sfchronicle.com/opinion/article/Let-s-open-the-door-to-Cuba-and-its -promising-6921055.php

  16. Arrencibia-Jorge R, Corera-Alvarez E, Chinchilla-Rodríguez Z, de Moya- Anegón F. Scientifi c output of the emerging Cuban biopharmaceutical industry: a scientometric approach. Scientometrics. 2016 May. DOI: 10.1007/s11192- 016-2023-1




2020     |     www.medigraphic.com